天辰生物 中
 
中

Home > News

Groundbreaking! Phase II Data of LP-003 Unveiled by Longbio Pharma at AAAAI2024

Groundbreaking! Phase II Data of LP-003 Unveiled by Longbio Pharma at AAAAI2024

Washington DC, US, Feb 25, 2024 – Longbio Pharma (Suzhou) Co., Ltd. (referred to as “Longbio Pharma”), a leading biotech company dedicated to developing innovative protein treatments for allergy, respiratory, dermatology, hematology, ophthalmology, and other autoimmune and rare diseases, proudly announced the release of preliminary Phase II data for LP-003, the new generation anti-IgE antibody, at the 2024 American Academy of Allergy, Asthma & Immunology annual meeting (AAAAI 2024).
Read More Groundbreaking! Phase II Data of LP-003 Unveiled by Longbio Pharma at AAAAI2024

Longbio Pharma Presented Positive Topline Phase 1 Results for LP-003 at ERS2023
SOFIA, Bulgaria, June 20, 2023 /PRNewswire/ -- Longbio Pharma (Suzhou) Co., Ltd. (abbreviated as "Longbio Pharma"), a pharmaceutical company that develops medicines for the treatment of allergy, asthma, ophthalmology and other autoimmune diseases, announced the preliminary phase I data of LP-003 (new generation of anti-IgE antibody) at the 29th Congress of European Rhinologic Society (ERS2023).
Read More Longbio Pharma Presented Positive Topline Phase 1 Results for LP-003 at ERS2023

Longbio to present during the 41th JPM Healthcare Conference
Longbio Pharma, a leading biotech company focused on autoimmune and rare diseases, will attend the 6th BFC Annual Global Healthcare Business Development and Investment Conference ("BFC Conference") on Sunday, January 8 (Pacific Standard Time, "PST") at St. Regis San Francisco during the 41th JP Morgan Healthcare Conference.
Read More Longbio to present during the 41th JPM Healthcare Conference

Phase II is coming! LP-003 is expected to become the first biomedicine to treat allergic rhinitis in China!
The discussion meeting of clinical protocol for the allergic rhinitis phase II clinical trial of LP-003 (registration number CTR20231145), led by Professor Wang Xueyan from Beijing Shijitan Hospital affiliated with Capital Medical University, was successfully held in Beijing in March 2023. Researchers from various centers participating in this clinical study actively and deeply discussed the the clinical protocol.
Read More Phase II is coming! LP-003 is expected to become the first biomedicine to treat allergic rhinitis in China!

The IND application of LP-005, the first complement pipeline of Longbio has accepted by the CDE
April 10, 2023, the IND application of innovative drug LP-005 was accepted by the CDE (centre for drug evaluation, NMPA) , and the application number is CXSL2300241. LP-005 is the first complementary drug of Longbio to receive an IND application acceptance from CDE, and will also be the company's third clinical stage drug. Longbio will continue to implement the company's dual drive strategy of "allergy and complement".
Read More The IND application of LP-005, the first complement pipeline of Longbio has accepted by the CDE
Platform
SunDoma™
InCibitor™
NeXine™
Science
Pipeline
LP-003
LP-005
All right sreserved@Longbio Pharma 沪CP备2021015040号